# Mineralys Therapeutics Adds Two Board Members Ahead of Key FDA Decision Date

- URL: https://stocks.freetheai.org/news/mineralys-therapeutics-adds-two-board-members-ahead-of-key-fda-decision-date-2c0802
- Published: 2026-10-19T20:05:00Z
- Category: company_news; sentiment: bullish; impact: low
- Symbols: [NASDAQ:MLYS](https://stocks.freetheai.org/symbols/NASDAQ-MLYS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) has appointed Kristine Peterson and Lonnel Coats to its board of directors. The additions strengthen the company leadership as it prepares for a potential commercial launch. Shares of Mineralys Therapeutics closed up 2.88% at $20.89 following the announcement.

Both new directors bring more than three decades of biopharmaceutical industry experience, with an emphasis on building commercial organizations and launching new therapies. Peterson previously served as Chief Executive Officer of Valeritas, Inc., and held senior roles at Johnson & Johnson, Biovail Corporation, and Bristol-Myers Squibb Company. Coats recently served as Chief Executive Officer of Lexicon Pharmaceuticals, Inc., and previously held executive positions at Eisai Inc. and Janssen Pharmaceuticals, Inc.

The board expansion arrives as Mineralys advances lorundrostat, an investigational oral therapy designed to target uncontrolled or resistant hypertension. The regulatory process for the drug faces a key target action date on December 22.

## Key points

- Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its board of directors.
- Both new members have over 30 years of biopharmaceutical commercialization experience.
- The appointments come ahead of a December 22 target action date for hypertension candidate lorundrostat.
- Shares of Mineralys Therapeutics rose 2.88% to $20.89 following the update.

## Questions and answers

### Who was appointed to the Mineralys Therapeutics board of directors?

Kristine Peterson and Lonnel Coats were appointed to the board of directors. Both bring over 30 years of biopharmaceutical commercialization experience.

### What is lorundrostat and when is its target decision date?

Lorundrostat is an investigational oral therapy being developed to treat uncontrolled or resistant hypertension. Its target decision date is December 22.

### What leadership experience do the new board members bring?

Kristine Peterson is the former CEO of Valeritas and held senior roles at Johnson & Johnson. Lonnel Coats is the former CEO of Lexicon Pharmaceuticals and led Eisai Inc. in North America.